0.912
price up icon0.22%   0.002
after-market Dopo l'orario di chiusura: .91 -0.002 -0.22%
loading
Precedente Chiudi:
$0.91
Aprire:
$0.92
Volume 24 ore:
73,258
Relative Volume:
0.50
Capitalizzazione di mercato:
$51.49M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.5124
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+11.22%
1M Prestazione:
+4.10%
6M Prestazione:
-24.94%
1 anno Prestazione:
-84.36%
Intervallo 1D:
Value
$0.8705
$0.9217
Intervallo di 1 settimana:
Value
$0.80
$0.9217
Portata 52W:
Value
$0.6101
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Nome
Prelude Therapeutics Inc
Name
Telefono
(302) 467-1280
Name
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Name
Dipendente
131
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
PRLD's Discussions on Twitter

Confronta PRLD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.912 51.38M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-19 Aggiornamento H.C. Wainwright Neutral → Buy
2024-06-20 Downgrade Barclays Equal Weight → Underweight
2024-03-13 Iniziato JMP Securities Mkt Outperform
2024-02-20 Downgrade H.C. Wainwright Buy → Neutral
2023-12-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2022-11-21 Downgrade BofA Securities Neutral → Underperform
2022-09-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-07-29 Iniziato Jefferies Buy
2022-03-15 Downgrade BofA Securities Buy → Neutral
2022-02-28 Downgrade Barclays Overweight → Equal Weight
2021-10-08 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-07-27 Aggiornamento BofA Securities Neutral → Buy
2021-04-26 Iniziato H.C. Wainwright Buy
2021-03-09 Iniziato Barclays Overweight
2020-11-20 Downgrade BofA Securities Buy → Neutral
2020-10-20 Iniziato BofA Securities Buy
2020-10-20 Iniziato Goldman Neutral
2020-10-20 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie

pulisher
Jul 24, 2025

Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Is Prelude Therapeutics Incorporated a good long term investmentExplosive capital appreciation - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks

Jul 24, 2025
pulisher
Jul 22, 2025

Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

What drives Prelude Therapeutics Incorporated stock priceDynamic profit opportunities - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser

Jul 19, 2025
pulisher
Jul 18, 2025

Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPro Trader Stock Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks

Jul 11, 2025
pulisher
Jun 27, 2025

Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks

Jun 27, 2025
pulisher
Jun 26, 2025

Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener

Jun 23, 2025
pulisher
Jun 17, 2025

Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus

Jun 17, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan

Jun 06, 2025
pulisher
Jun 04, 2025

Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech

Jun 04, 2025
pulisher
Jun 04, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance

Jun 02, 2025
pulisher
May 28, 2025

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India

May 27, 2025

Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):